Pfizer Inc
PFE:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 30.47 | -0.26 -0.85% | 3.38% | 42,560 | 25.1M |
Recent News Headlines for Pfizer Inc
- Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis(R) (apixaban) in Patients with NVAF Undergoing Cardioversion
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--July 17, 2014-- Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion (administered through electric shock to the chest or with medication) is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively. Traditionally, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward. In some patients, early cardioversion can be performed on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke.
- Bristol-Myers Squibb and Pfizer Announce -2-
aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. PREGNANCY CATEGORY B There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
- #FOGO? -- New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) -- Results Show Top Fear is Decline in Physical Ability(1)
Pfizer's Get Old Campaign Challenges Conventional Attitudes about Aging New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2) NEW YORK--(BUSINESS WIRE)--July 16, 2014--
- Pfizer to Acquire InnoPharma, Inc.
- Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
- Biotechnology Sector Trends Higher with -2-
- Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R) ) Once-Weekly Prophylaxis For Hemophilia B
- Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics
- Kosher Certifications, Biologic License Applications, Positive Study Results, Development Programs, and Product Acquisitions - Analyst Notes on Pfizer, Novartis, Sanofi, Zogenix and Impax
- Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus
- Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
- Eliquis(R) (apixaban) Receives CHMP Positive -2-
- Conference Call Schedules, Disclosures, Partnerships, and Acquisitions - Analyst Notes on Pfizer, Covidien, UnitedHealth Group, Alexion and Abbott
- Pfizer Declares 26-Cent Third-Quarter 2014 Dividend
- James C. Smith Elected to Pfizer's Board of Directors